Share this page
www.indivumed.com/about-us/network/

The oncology alliance for individualized medicine

Innovation is built on collaboration.

Onco AI-Med is a collaborative network of leading oncologists and cancer researchers that has its origins in the many scientific relationships we have established throughout our two-decade history. The network brings together the experiences, perspectives, and talents of experts from different countries and backgrounds to share ideas, explore new technologies, and advance the concept of precision medicine for the benefit of cancer patients all over the world.

Why we have the power to unlock the secrets of cancer.

Interview with Dr. John Marshall, Chairman Onco AI-Med Advisory Board

Onco AI-Med advisory boardCancer research at the highest level

Members of the network are motivated by a shared passion for advancing precision oncology. We are convinced that by exchanging knowledge and ideas and working together across disciplines in an open and collaborative way, we can achieve our goals faster and more comprehensively. To ensure relevance and provide direction, the activities of the network are coordinated by an advisory board that includes some of the brightest experts in clinical translational oncology research today.

Dr. John Marshall (Chairman)

Chief, Division of Hematology/Oncology, Georgetown University Hospital, USA

“The Onco AI-Med group has the power to unlock the secrets of cancer. I’ve never been prouder to work with a group of people!”

Dr. John Marshall
Chairman, Onco AI-Med advisory board

Dr. Jesus Garcia-Foncillas

Director, OncoHealth Institute; Director, Department of Oncology; Director, Translational Oncology Division, Jiménez Díaz Foundation University Hospital, Madrid, Spain

Dr. Sun Young Rha

Chief, Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Seoul, South Korea

Dr. David Kerr

Professor of Cancer Medicine, University of Oxford, Honorary Consultant Medical Oncologist, Oxford University Hospitals Trust, UK

Dr. Takayuki Yoshino

Director for the Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Japan

Prof. David Gallagher

Consultant Oncologist and Geneticist, St. James Hospital, Mater Private Hospital; Professor, Trinity College, Dublin, Ireland

Prof. Gerry Melino

Professor of Biochemistry, University of Rome Tor Vergata; Director of Torvergata Oncoscience Research Center, Rome, Italy

“The Onco AI-Med board is a fantastic example of what we can do with truly international cooperation.”

Dr. David Kerr Professor of Cancer Medicine, University of Oxford

MediaLearn more about the work of Onco AI-Med.